RMAT vs Breakthrough Therapy Designation: Differences and Strategic Selection
RMAT (Regenerative Medicine Advanced Therapy) designation and breakthrough therapy designation (BTD) are both FDA expedited programs that provide intensive FDA guidance, rolling review eligibility, and priority review. The key differences are: (1) RMAT is limited to regenerative medicine therapies (cell therapy, gene therapy, tissue engineering), while BTD applies to any drug or biologic; (2) RMAT eligibility requires only "potential to address unmet medical needs" based on preliminary clinical evidence, whereas BTD requires "preliminary clinical evidence of substantial improvement" over existing therapy; and (3) RMAT explicitly facilitates the use of surrogate or intermediate endpoints for accelerated approval. Both designations can be held simultaneously, and doing so maximizes available FDA support.
Key Takeaways
Key Takeaways
- RMAT applies only to regenerative medicine therapies (cell therapy, gene therapy, tissue engineering) and has a lower evidence bar ("potential to address unmet need") compared to BTD ("substantial improvement")
- Both designations provide identical operational benefits: intensive FDA guidance, rolling review, priority review eligibility, and senior management involvement
- RMAT has a unique statutory provision explicitly facilitating accelerated approval via surrogate or intermediate endpoints under Section 506(g) of the FD&C Act
- Products can hold both RMAT and BTD simultaneously; pursuing dual designation maximizes regulatory support and flexibility
- RMAT vs breakthrough therapy is a strategic decision facing every developer of cell therapy, gene therapy, and regenerative medicine products. Both designations offer significant regulatory advantages, but they differ in eligibility criteria, specific benefits, and application strategy. For products that qualify for both, pursuing dual designation provides the broadest set of regulatory tools.
- This guide provides a detailed comparison of the two designations, including eligibility criteria, benefits, application process, and a decision framework for strategic selection.
- In this guide, you will learn:
- The statutory basis and eligibility criteria for each designation
- A head-to-head comparison of benefits
- When to pursue RMAT, BTD, or both
- Application process and timing for each
- Current statistics on designation grants
- Strategic considerations for dual designation
- ---
Regenerative Medicine Advanced Therapy: RMAT Designation Explained
Regenerative Medicine Advanced Therapy (RMAT) designation is an FDA expedited program established by Section 3033 of the 21st Century Cures Act (December 13, 2016), codified at Section 506(g) of the FD&C Act (21 U.S.C. 356(g)). It applies to regenerative medicine therapies that are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates potential to address unmet medical needs.
RMAT Eligibility Criteria
| Criterion | Requirement | Detail |
|---|---|---|
| Product type | Regenerative medicine therapy | Cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies; gene therapy (including genetically modified cells) |
| Condition | Serious or life-threatening disease or condition | Consistent with FDA's definition of serious condition (substantial morbidity impact) |
| Evidence | Preliminary clinical evidence indicates potential to address unmet medical needs | Lower bar than BTD; "potential" rather than demonstrated improvement |
What Qualifies as a Regenerative Medicine Therapy?
The 21st Century Cures Act defines regenerative medicine therapy broadly:
| Product Category | RMAT Eligible? | Examples |
|---|---|---|
| Cell therapy | Yes | Expanded stem cells, modified immune cells, somatic cell therapies |
| Gene therapy | Yes | AAV gene therapy, lentiviral gene therapy, gene editing |
| Genetically modified cells | Yes | CAR-T, TCR-T, gene-edited cells |
| Therapeutic tissue engineering | Yes | Tissue-engineered skin, cartilage, organs |
| Human cell and tissue products | Yes | When meeting criteria beyond 361 HCT/P |
| Combination products | Yes | If containing a regenerative medicine therapy component |
| Small molecule drugs | No | Even if treating conditions relevant to regenerative medicine |
| Conventional biologics (mAbs, cytokines) | No | Not classified as regenerative medicine therapy |
RMAT Benefits
| Benefit | Description |
|---|---|
| All Fast Track features | Frequent FDA meetings, rolling review, written FDA feedback |
| All Breakthrough Therapy features | Intensive FDA guidance, senior management involvement, cross-disciplinary engagement |
| Accelerated approval facilitation | FDA will discuss use of surrogate or intermediate endpoints for approval |
| Priority review eligibility | 6-month review instead of 10-month standard |
| Post-approval flexibility | Discussions regarding how to fulfill post-approval requirements |
As of September 2025, FDA has granted approximately 90 RMAT designations since the program began in 2017. The grant rate has been approximately 30-35% of requests submitted. Gene therapies and cell therapies (including CAR-T) account for the majority of RMAT designations granted.
RMAT Designation: Application Process
How to Request RMAT Designation
| Element | Details |
|---|---|
| Submission | Request submitted under the IND (21 CFR 312.310 does not apply; submit as IND correspondence) |
| Timing | Any time after IND filing; most effective early in development |
| Format | Written request with supporting data package |
| Review timeline | FDA targets response within 60 calendar days |
| Review center | CBER OTP for cell and gene therapy products |
RMAT Request Content
| Section | Required Content |
|---|---|
| Product description | Type of regenerative medicine therapy, mechanism of action, vector/cell type |
| Indication | Target disease or condition, why it is serious or life-threatening |
| Unmet medical need | What currently available therapies exist; what need is unaddressed |
| Preliminary clinical evidence | Clinical data (Phase 1, Phase 2, or case series) indicating potential to address unmet need |
| Development plan | Proposed clinical development strategy |
| Specific request | Explicit request for RMAT designation under Section 506(g) |
Evidence Requirements for RMAT
The evidentiary standard for RMAT is deliberately lower than for breakthrough therapy:
| Evidence Type | Acceptability for RMAT | Comparison to BTD |
|---|---|---|
| Phase 1 safety data with efficacy signals | Sufficient if indicating potential | May be sufficient for BTD in oncology/rare disease |
| Phase 1/2 data showing clinical response | Strong evidence | Standard BTD evidence |
| Case series or compassionate use data | May be sufficient | Generally insufficient for BTD |
| Biomarker data (non-validated) | May support request | Generally insufficient alone for BTD |
| Preclinical data alone | Insufficient (clinical evidence required) | Insufficient for BTD |
| Published literature | Can supplement | Can supplement |
When submitting an RMAT request, clearly articulate the "unmet medical need" component. Unlike BTD, RMAT does not require demonstration of "substantial improvement" over existing therapy. Instead, you must show that no existing therapy adequately addresses the need. For diseases with no approved therapy, this is straightforward. For diseases with approved therapies that have significant limitations (toxicity, durability, subpopulation non-response), articulate specifically why the unmet need persists despite available treatments.
RMAT vs BTD: Head-to-Head Comparison
Eligibility Comparison
| Criterion | RMAT | BTD |
|---|---|---|
| Product scope | Regenerative medicine therapies only | Any drug or biologic |
| Statutory basis | 21st Century Cures Act Section 3033 (2016) | FDASIA Section 902 (2012) |
| Regulatory citation | 21 U.S.C. 356(g) | 21 U.S.C. 356(a) |
| Condition | Serious or life-threatening | Serious or life-threatening |
| Evidence standard | Preliminary clinical evidence of POTENTIAL to address unmet medical need | Preliminary clinical evidence of SUBSTANTIAL IMPROVEMENT on clinically significant endpoint |
| Comparator requirement | Demonstrate unmet need (no comparator required) | Demonstrate improvement OVER available therapy |
| Evidence bar | Lower | Higher |
Benefits Comparison
| Benefit | RMAT | BTD | Difference |
|---|---|---|---|
| Frequent FDA meetings | Yes | Yes | Same |
| Rolling review | Yes | Yes | Same |
| Intensive FDA guidance | Yes | Yes | Same |
| Senior management involvement | Yes | Yes | Same |
| Cross-disciplinary engagement | Yes | Yes | Same |
| Priority review eligibility | Yes | Yes | Same |
| Accelerated approval discussion | Explicit statutory provision | Available but not explicitly linked | RMAT has stronger statutory link |
| Surrogate/intermediate endpoint discussion | Explicit statutory provision | Available through accelerated approval | RMAT has explicit Cures Act provision |
| Post-approval requirement discussion | Explicit statutory provision | Standard post-marketing requirements | RMAT provides explicit mechanism |
Key Differentiators
1. Lower Evidence Bar for RMAT
RMAT requires "potential to address unmet medical needs" while BTD requires "substantial improvement on clinically significant endpoint." This means RMAT may be obtainable earlier in development, with less mature clinical data.
2. Explicit Accelerated Approval Link for RMAT
Section 506(g)(2) of the FD&C Act specifically states that FDA shall discuss with the sponsor use of surrogate or intermediate endpoints for accelerated approval. While accelerated approval is available to any product, the explicit statutory provision for RMAT reinforces FDA's commitment to consider it for regenerative medicine therapies.
3. Post-Approval Flexibility for RMAT
Section 506(g)(5) states that FDA shall facilitate discussions regarding how to fulfill post-approval requirements, including potential for use of real-world evidence. This provision is unique to RMAT.
4. Product Limitation for RMAT
RMAT is only available for regenerative medicine therapies. A monoclonal antibody, for example, could receive BTD but not RMAT. This limitation is offset by the lower evidence bar for eligible products.
Strategic Selection: When to Pursue Which Designation
Decision Framework
| Scenario | Recommended Designation | Rationale |
|---|---|---|
| Cell/gene therapy with early clinical data and no approved therapy | RMAT first, then BTD when data matures | Lower evidence bar for RMAT allows earlier designation |
| Cell/gene therapy with Phase 2 data showing substantial improvement | Both RMAT and BTD simultaneously | Mature data supports both; dual maximizes benefits |
| Cell/gene therapy in disease with approved therapies | BTD (if data shows improvement); RMAT (if unmet need persists) | Strategy depends on whether improvement can be demonstrated |
| Conventional biologic (mAb, cytokine) | BTD only | Not eligible for RMAT |
| Small molecule for regenerative application | BTD only | Not eligible for RMAT |
| Gene therapy with only Phase 1 safety data and efficacy signal | RMAT | BTD may be premature; RMAT lower bar may be met |
| CAR-T for heavily pretreated population | Both RMAT and BTD | Strong case for both (regenerative + improvement vs. no effective alternative) |
Dual Designation: Strategy and Benefits
Products can hold both RMAT and BTD simultaneously. There is no regulatory restriction on dual designation.
| Dual Designation Advantage | How It Helps |
|---|---|
| Maximal FDA engagement | Triggers the strongest possible FDA support commitment |
| Accelerated approval | Dual designation reinforces eligibility for surrogate endpoint approval |
| Rolling review | Confirmed from both designations |
| Regulatory flexibility | If one designation is rescinded, the other remains |
| Market positioning | Both designations carry recognition and credibility |
Timing strategy for dual designation:
- Submit RMAT request first (after Phase 1 data with efficacy signal)
- Submit BTD request when Phase 2 data demonstrates substantial improvement
- Reference RMAT in BTD request to show consistency and program development
If you have Phase 2 data showing substantial improvement, submit RMAT and BTD requests simultaneously in separate submissions to the IND. There is no requirement to wait for one response before submitting the other. CBER reviews them independently, and both decisions will be issued within 60 days of their respective submission dates.
Comparison with Other Expedited Programs
All FDA Expedited Programs
| Program | Eligible Products | Evidence Requirement | Key Benefit | RMAT Compatible? |
|---|---|---|---|---|
| RMAT | Regenerative medicine therapies | Preliminary clinical evidence of potential | Accelerated approval discussion, all BT features | N/A |
| Breakthrough Therapy | Any drug/biologic | Preliminary clinical evidence of substantial improvement | Intensive FDA guidance, rolling review, priority review | Yes |
| Fast Track | Any drug/biologic | Nonclinical or clinical data, serious condition with unmet need | Frequent meetings, rolling review | Yes |
| Accelerated Approval | Any drug/biologic | Surrogate/intermediate endpoint reasonably likely to predict clinical benefit | Approval based on surrogate endpoint | Yes |
| Priority Review | Any drug/biologic | Significant improvement in safety/effectiveness | 6-month review (vs. 10 months) | Yes |
Stacking Designations
| Combination | Feasibility | Notes |
|---|---|---|
| RMAT + BTD | Yes, commonly pursued | Maximum benefits |
| RMAT + Fast Track | Yes, RMAT includes all FT benefits | RMAT subsumes FT |
| RMAT + Accelerated Approval | Yes, RMAT facilitates discussion | RMAT explicitly links to AA |
| RMAT + Priority Review | Yes | Included in RMAT benefits |
| RMAT + Orphan Drug Designation | Yes | Independent programs; additive benefits |
| BTD + Fast Track | Yes, BTD includes all FT benefits | BTD subsumes FT |
| BTD + Accelerated Approval | Yes | Available when using surrogate endpoint |
Application Timing and Statistics
Optimal Application Timing
| Designation | Optimal Timing | Data Typically Available |
|---|---|---|
| RMAT | Late Phase 1 / Early Phase 2 | Phase 1 safety + efficacy signal |
| BTD | End of Phase 1 / Phase 2 | Controlled or uncontrolled data showing substantial improvement |
| Both | When Phase 2 data shows clear improvement | Sufficient data for both standards |
Current Statistics
| Metric | RMAT | BTD |
|---|---|---|
| Program inception | 2017 (Cures Act 2016) | 2013 (FDASIA 2012) |
| Total requests (through Sept 2025) | ~270 | ~1,622 |
| Total granted (through Sept 2025) | ~90 | ~634 |
| Grant rate | ~30-35% | ~39% |
| Products approved with designation | ~15 | ~336 |
| Common product types | Gene therapy, CAR-T, cell therapy | Oncology, rare disease, across product types |
The RMAT grant rate of approximately 30-35% is slightly lower than the BTD grant rate of approximately 39%. This may reflect the novelty of regenerative medicine products and the challenges in generating clinical evidence for some cell and tissue engineering products. For gene therapies and CAR-T products specifically, the grant rates for both RMAT and BTD trend higher than the overall averages.
RMAT-Specific Advantage: Surrogate and Intermediate Endpoints
One of RMAT's most significant unique provisions is the explicit statutory facilitation of accelerated approval based on surrogate or intermediate clinical endpoints.
Surrogate Endpoint Considerations for Regenerative Medicine
| Product Type | Potential Surrogate Endpoints | Regulatory Precedent |
|---|---|---|
| CAR-T (oncology) | Overall response rate, complete response rate | Abecma, Breyanzi approved on ORR |
| Gene therapy (hemophilia) | Factor VIII/IX activity levels | Hemgenix approved based on factor levels |
| Gene therapy (retinal) | Multi-luminance mobility test | Luxturna approved based on functional vision |
| Gene therapy (SMA) | Motor milestone achievement | Zolgensma approved based on milestones |
| Cell therapy (orthopedic) | Structural repair on imaging | Limited precedent; FDA discussion encouraged |
| Gene therapy (sickle cell) | Fetal hemoglobin levels, VOC-free period | Casgevy/Lyfgenia approved |
Post-Approval Requirements Under RMAT
When a product is approved under accelerated approval with RMAT designation, the post-approval requirements may include:
| Requirement Type | Description |
|---|---|
| Confirmatory study | Required to verify clinical benefit (standard for accelerated approval) |
| Real-world evidence | RMAT provision allows discussion of using RWE for confirmatory evidence |
| Patient registry | May be required to track long-term outcomes |
| Post-marketing study | Standard PMR/PMC as appropriate |
References
Yes. RMAT and BTD are not mutually exclusive. A regenerative medicine therapy can hold both designations simultaneously. This is strategically advantageous because it maximizes FDA engagement and regulatory flexibility. Several approved products (including CAR-T therapies) have held dual designation.